<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30943147</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0392-856X</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Clinical and experimental rheumatology</Title><ISOAbbreviation>Clin Exp Rheumatol</ISOAbbreviation></Journal><ArticleTitle>IL-6 and TGF-&#x3b2; gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>963</StartPage><EndPage>975</EndPage><MedlinePgn>963-975</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of the study was to explore whether TGF-&#x3b2; and IL-6 gene polymorphisms may be associated with SLE and assess the frequency of HLA-DRB1 alleles in Polish systemic lupus erythematosus (SLE) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">216 SLE patients and 552 healthy individuals were examined for TGF-&#x3b2; rs1800469 and rs1800470 by TaqMan SNP genotyping assay and for and IL-6(rs2069827 and rs1800795 using the PCR- RFLP method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An increased frequency of TT genotype and T allele of the TGF &#x3b2; -509 C/T was found in SLE patients (p=0.02). The TGF-&#x3b2; 869 C allele was more frequent in SLE patients. The genotype-phenotype analysis showed association between the TGF &#x3b2; -509 C/T and mean value of CRP, ESR, haemoglobin, APTT, Pt and INR (p=0.05, p=0.03, p&lt;0.001, p=0.03, p=0.03 and p=0.05, respectively) as well as anti-SSA and anti-Sm presence (p=0.04 and p=0.03, respectively); the TGF- &#x3b2; 869 T/C and mean value of APTT and INR (p=0.01 and p=0.05, respectively); the IL-6 -174 G/C and SLICC (p=0.05), anti-SSA (p=0.05) and anti-SSB (p=0.05). A higher TGF-&#x3b2; and IL-6 serum level were found in SLE patients compared to controls (both p&lt;0.0001). In SLE patients with the TGF-&#x3b2; -509 TT genotype have shown positive association with the TGF-&#x3b2; serum levels. Polish SLE patients have strong positive association with HLA-DRB1*52.1, and negative with the HLA-DRB1*07:01 allele. HLA-DRB1*52.1 was also associated with higher TGF-&#x3b2; serum levels in the Polish population.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggested that the TGF &#x3b2; -509 C/T variant may be considered as a genetic marker for SLE in the Polish population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paradowska-Gorycka</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. paradowska_aga@interia.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roszak</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stypinska</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutkowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walczyk</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olesinska</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wajda</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piotrowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan; and Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puszczewicz</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Internal Diseases, Poznan University of Medical Science, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majewski</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Internal Diseases, Poznan University of Medical Science, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagodzinski</LastName><ForeName>Pawel Piotr</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Rheumatol</MedlineTA><NlmUniqueID>8308521</NlmUniqueID><ISSNLinking>0392-856X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="Y">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30943147</ArticleId><ArticleId IdType="pii">13147</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>